Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426562 | 0.89 | ALDH1A1 (0.56) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 | |
| SCHEMBL17221228 | 0.83 | KLKB1 (0.58) | PARP1ALDH1A1KLKB1KMT2AKDM4E | |
| SCHEMBL4544356 | 0.80 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1KLKB1ADORA2AADORA3 | |
| SCHEMBL23212135 | 0.80 | PARP1 (0.56) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 | |
| SCHEMBL11479831 | 0.79 | PARP1 (0.55) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 | |
| SCHEMBL30739027 | 0.77 | PARP1 (0.54) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 | |
| SCHEMBL2268172 | 0.77 | PARP1 (1.00) | PARP1 | |
| SCHEMBL30739115 | 0.76 | PARP1 (0.53) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 | |
| SCHEMBL8756843 | 0.76 | ADORA2A (0.53) | PARP1ALDH1A1L3MBTL1ADORA2AADORA3 | |
| SCHEMBL30739088 | 0.76 | PARP1 (0.52) | PARP1ALDH1A1L3MBTL1KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | PARP1 1258/4885ALDH1A1 3689/4885L3MBTL1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.